Health Economics and Outcomes Research (HEOR) as a tool for improving operational performance and competitive advantage
ESiOR Ltd provides companies, service providers and other entities operating in social care and healthcare with expert solutions, services, tools and consulting to aid decision making, management and marketing. Our expert services provide the means to identify, demonstrate, communicate and improve the competitiveness of products, services, processes and networks.
Benefit from our competence
ESiOR has considerable expertise and extensive experience in the key methods, solutions and approaches that enable knowledge management and competitive differentiation.
Our areas of expertize
- social and health economics
- outcomes research
- economic evaluation
- health technology assessments (HTA)
- cost-effectiveness analyses
- budget impact tools
- mathematical modelling
- goal setting
- data management
The full scope of our services varies from consulting to turnkey solutions encompassing design, analysis, model development, reporting, publication and communication.
We specialize in:
- commissioned research
- registry studies
- systematic literature reviews and meta-analysis
- health economic evaluations
- local and global modelling and model development
- localizations and country adaptations for global health economic models.
In addition to health economic evaluations, we now offer Market Access services. These include, among others, all pricing and reimbursement applications and comprehensive consultancy.
From data to competitive advantage
The characteristics of products, services, programmes and networks can be made to stand out and they can be differentiated from their competitors with a unique selling point.
Sources for distinctive advantages:
- customer experience
- quality of life
- cost containment
- target attainment
- budget impact
- key performance indicators (KPI)
- other outcomes.
Differentiation is an essential part of having a competitive advantage.
Well-known Market Access professionals, Satu Rauhala and Akseli Kivioja, joined ESiOR on August 7th, 2017. Their joint experience is unique: Finnish Pharmaceuticals Pricing Board, pharma industry, pharmaceutical research, and consultancy. When you are in need of experience, expertise and broad vision, please don’t hesitate to contact us. Additional information: Akseli Kivioja, Satu Rauhala or Erkki Soini
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a collaborative effort by ESiOR Oy, Abbvie Oy, The Crohn and Colitis association (Crohn ja Colitis ry), Confederation of Finnish Industries (EK), The Finnish Medical Association, The Finnish Rheumatism Association, SITRA, […]